Cash Injection Puts Quell At Forefront Of Treg Therapy
Series B Raises $156m
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.